Navigation Links
Merz Pharmaceuticals Commends The Benign Essential Blepharospasm Research Foundation On 30 Years Of Community Support

GREENSBORO, N.C., July 22, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC, commends the Benign Essential Blepharospasm Research Foundation (BEBRF) for 30 years of dedication to increasing awareness of blepharospasm, a neurological disorder that causes abnormal, involuntary spasms of the muscles around the eye, and raising funds for research. Founded on July 23, 1981, BEBRF has grown to be an invaluable resource for the blepharospasm community.

Many people living with blepharospasm have spent months or even years experiencing the symptoms of uncontrollable eyelid blinking before receiving an accurate diagnosis. It was a similar delay in diagnosis and an overall lack of awareness among both physicians and the public that motivated Mattie Lou Koster to form BEBRF 30 years ago. Today, her daughter Mary Lou Thompson continues to lead the organization, which aims to undertake, promote, develop and carry on the search for the cause and a cure for blepharospasm.

"I'm so pleased to celebrate how far BEBRF has come in the past 30 years," said Mary Lou, President of BEBRF. "It's been such an honor for me to continue my mother's goal of creating a foundation that addresses the needs of patients while raising awareness of blepharospasm so it becomes more easily recognized. I thank the remarkable members of the blepharospasm community and our supportive partners for all of their hard work over the years."

Through a network of local support groups, educational activities and collaboration with other organizations that have similar goals, BEBRF has had a significant impact on the blepharospasm community. The symposiums, newsletters, website, pamphlets and other materials provided by the organization have been influential in helping people better understand their diagnosis while raising awareness of the condition.

"BEBRF has bettered the lives of blepharospasm sufferers and their families worldwide in the last 30 years," said Richard L. Anderson, M.D., F.A.C.S., Center for Facial Appearances, Salt Lake City, Utah. "I look forward to seeing the advances made by BEBRF in the next three decades and I am very proud to be on the Board of this foundation."

In an effort to continue bringing resources to people with blepharospasm across the U.S., Merz Pharmaceuticals will expand its support of BEBRF beyond the national level by providing assistance to local BEBRF support groups.  For more information about how Merz can assist your local blepharospasm support group, please contact Merz Professional Services at 1-800-334-0514.

"When I was first diagnosed with blepharospasm nearly 25 years ago, I didn't know where to go for more information," said Anita Croce, BEBRF North Central District Director. "My doctor referred me to BEBRF and since then, I've been working closely with the Foundation to ensure others living with this condition know they're not alone. I'm proud to have seen BEBRF mature from the beginning years to where we are today, with undaunted dedication to empowering patients and providing opportunities to share experiences, encouragement, hope and knowledge."

Although there is no cure for blepharospasm at this time, there are treatments available, including botulinum toxin injections, drug therapy and surgery.

"On this occasion of the 30th anniversary of BEBRF, I wish the foundation continued success in its pursuit of the primary mission to improve the quality of life of each and every person living with blepharospasm through support of research, education and services," said Joseph Jankovic, M.D., Director of the Parkinson's Disease Center and Movement Disorders Clinic at Baylor College of Medicine, Houston, Texas. "For me, being a founding member and the first Chairman of the Medical Advisory Board of the BEBRF, and having the privilege to know Mattie Lou and Mary Lou, have been among the most rewarding experiences in my personal and professional life, for which I will always be grateful."

For more information about BEBRF, including local support group meetings, visit

About Blepharospasm    

Blepharospasm is a rare neurological disorder that affects the muscles around the eye that are used to blink. It can result in involuntary contractions in the eyelids which can vary from an increased blink rate and intermittent eyelid spasm to eyelid closing for most of the day. Blepharospasm usually begins in the fifth to sixth decade of life and is more common in women than in men.

According to an epidemiology study conducted in Rochester, Minn. focal dystonia (which includes cervical dystonia and blepharospasm) is estimated to affect 295 per million people in the U.S.

About Merz

Merz Pharmaceuticals, LLC is a part of the Merz Group of companies and was established in 1995 to develop and commercialize products for the Merz Group. Areas of therapeutic focus include Neurology, Physiatry, Dermatology, and Podiatry.

With over a century of heritage, the Merz Group is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in the development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic medicine. Global research is concentrated in fields that have a strong need for therapeutic innovation such as Alzheimer's disease, Parkinson's disease, tinnitus, chronic pain conditions, addictions, and neuromuscular disturbances.

SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
2. Vanda Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011
3. ReportsnReports - The Outlook for Pharmaceuticals (BRIC, Asia, Europe, E7)
4. Amylin Pharmaceuticals to Webcast Second Quarter Results
5. Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta™ in Canada
6. Access Pharmaceuticals MuGard Included in TRICARE Prescription Drug Coverage
7. Auxilium Pharmaceuticals to Announce Second Quarter 2011 Results and Conduct Conference Call on Monday, August 1, 2011
8. Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics
9. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
10. Cumberland Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011
11. Access Pharmaceuticals MuGard Added to CVS Caremarks Pharmacy Benefit Network
Post Your Comments:
(Date:10/13/2015)... 13, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... Cell Therapy Catapult to advance development of large ... cell immunotherapy. Under the agreement, the Cell Therapy ... AST-VAC2 to support advanced clinical trials and eventual ... --> The Cell Therapy Catapult is ...
(Date:10/12/2015)... 13, 2015 the United States ... a non-clinical capacity. --> the United States ... a non-clinical capacity. --> The University of Texas MD ... the first high field (1.5 Tesla) MRI-guided linear accelerator in ... system will be operating in a non-clinical capacity. Royal ...
(Date:10/12/2015)... 2015 Given the intricacy of the ... to deliver an ophthalmic drug effectively to a specific ocular ... ocular drug delivery. These include dilution of a drug by ... conjunctiva and drug permeation issues with respect to the cornea, ... eye drops, is lost due to the aforementioned barriers. ...
Breaking Medicine Technology:
(Date:10/12/2015)... , ... October 12, 2015 , ... Advera Health ... no charge to qualified Managed Care Organizations (MCOs) in order to provide health plans, ... into their decision making process. In addition, the DSM is also being offered to ...
(Date:10/12/2015)... ... October 12, 2015 , ... To ... announced its charitable donation to the National Breast Cancer Foundation. The National Breast ... by breast cancer through early detection, education, and support services. , The annual ...
(Date:10/12/2015)... ... ... Clara dentist , Dr. Alan Frame, shares his insight on today’s dental hygiene and the ... “I want each one of my patients to be at their optimum level of health, ... implants dentist , Dr. Frame. He mentions, "As the white paper mentions, oral health care ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... receive a Eugene Washington Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) ... the research community. , The project, entitled “Training Patients with Asthma to ...
(Date:10/12/2015)... ... October 12, 2015 , ... ... secured a new corporate headquarters, located at 485 Madison Avenue, New York, NY ... and increased emphasis on cloud-based technology. , “Care to Care is a dynamic ...
Breaking Medicine News(10 mins):